These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1143 related articles for article (PubMed ID: 21802367)
1. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Hamers RL; Wallis CL; Kityo C; Siwale M; Mandaliya K; Conradie F; Botes ME; Wellington M; Osibogun A; Sigaloff KC; Nankya I; Schuurman R; Wit FW; Stevens WS; van Vugt M; de Wit TF; Lancet Infect Dis; 2011 Oct; 11(10):750-9. PubMed ID: 21802367 [TBL] [Abstract][Full Text] [Related]
2. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya. Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281 [TBL] [Abstract][Full Text] [Related]
3. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia. Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970 [TBL] [Abstract][Full Text] [Related]
4. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R; Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603 [TBL] [Abstract][Full Text] [Related]
5. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546 [TBL] [Abstract][Full Text] [Related]
6. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial. Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS; PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032 [TBL] [Abstract][Full Text] [Related]
7. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Hamers RL; Schuurman R; Sigaloff KC; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Wit FW; van Vugt M; Stevens WS; de Wit TF; Lancet Infect Dis; 2012 Apr; 12(4):307-17. PubMed ID: 22036233 [TBL] [Abstract][Full Text] [Related]
8. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Paton NI; Kityo C; Thompson J; Nankya I; Bagenda L; Hoppe A; Hakim J; Kambugu A; van Oosterhout JJ; Kiconco M; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Lancet HIV; 2017 Aug; 4(8):e341-e348. PubMed ID: 28495562 [TBL] [Abstract][Full Text] [Related]
9. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study. Mulu A; Maier M; Liebert UG PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902 [TBL] [Abstract][Full Text] [Related]
10. Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013. McCluskey SM; Lee GQ; Kamelian K; Kembabazi A; Musinguzi N; Bwana MB; Muzoora C; Haberer JE; Hunt PW; Martin JN; Boum Y; Bangsberg DR; Harrigan PR; Siedner MJ AIDS Patient Care STDS; 2018 Jul; 32(7):257-264. PubMed ID: 29985647 [TBL] [Abstract][Full Text] [Related]
11. High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children. Boerma RS; Boender TS; Sigaloff KC; Rinke de Wit TF; van Hensbroek MB; Ndembi N; Adeyemo T; Temiye EO; Osibogun A; Ondoa P; Calis JC; Akanmu AS J Int AIDS Soc; 2016; 19(1):21140. PubMed ID: 27836020 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya. Makwaga O; Adhiambo M; Mulama DH; Muoma J; Adungo F; Wanjiku H; Ongaya A; Maitha GM; Mwau M Pan Afr Med J; 2020; 37():311. PubMed ID: 33654530 [TBL] [Abstract][Full Text] [Related]
13. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. TenoRes Study Group Lancet Infect Dis; 2016 May; 16(5):565-575. PubMed ID: 26831472 [TBL] [Abstract][Full Text] [Related]
14. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]